OMNIAMED Logo
COMPANY
Overview
CEO Message
Leadership
Partners
CI
Contact Us
R&D
R&D Overview
Pipeline Overview
Tech 1
Tech 2
Tech 3
PR
Press Release
Publications
Intellectual Property
RECRUIT
Careers
HOME
CONTACT US
ENG
ENG
KOR
COMPANY
Overview
CEO Message
Leadership
Partners
CI
Contact Us
R&D
R&D Overview
Pipeline Overview
Tech 1
Tech 2
Tech 3
PR
Press Release
Publications
Intellectual Property
RECRUIT
Careers
R&D
OmniaMed Co., Ltd. opens up a new paradigm for
the development of treatments using Nitric Oxide functionality.
R&D Overview
Pipeline Overview
Tech1
Tech2
Tech3
Tech2
NO is an important signaling substance in the immune response of inflammation and tumor sites.
Inflammation and tumor-related diseases, NO is mostly over-expressed.
The effectiveness of several treatments is limited by the different actions of over-expressed NO.
Tech 2 eliminates NO in microenvironments to maximize therapeutic effectiveness of existing treatments